Results 31 to 40 of about 830,895 (193)

EVALUATION OF HISTONE DEACETYLASE INHIBITOR EFFECTS ON THYROID CANCER [PDF]

, 2009
Histone deacetylases (HDACs) play a crucial role in the proper regulation of cellular functions through their connection with chromatin and transcriptional regulation.
Borbone, Eleonora
core   +1 more source

Genome-scale network model of metabolism and histone acetylation reveals metabolic dependencies of histone deacetylase inhibitors

Genome Biology, 2019
Histone acetylation plays a central role in gene regulation and is sensitive to the levels of metabolic intermediates. However, predicting the impact of metabolic alterations on acetylation in pathological conditions is a significant challenge.
Fangzhou Shen, Luigi Boccuto, Rini Pauly, Sujata Srikanth, Sriram Chandrasekaran   +4 more
doaj   +1 more source

The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo [PDF]

, 2008
Histone deacetylase (HDAC) inhibitors represent a promising class of antineoplastic agents which affect tumour growth, differentiation and invasion. The effects of the HDAC inhibitor valproic acid (VPA) were tested in vitro and in vivo on pre-clinical ...
Eva Juengel, Mickuckyte, Ausra, Hudak, Lukasz, Jones, Jon, Lukasz Hudak, Jüngel, Eva, Dietger Jonas, Blaheta, Roman A., Roman A. Blaheta, Wedel, Steffen Alexander, Ausra Mickuckyte, Jonas, Dietger, Jon Jones, Steffen Wedel   +13 more
core   +1 more source

The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma

, 2010
Recent improvements in molecular sub typing of Non Hodgkin’s lymphomashave resulted in targeted therapies becoming incorporated into treatmentparadigms.
Nolan, David Francis Luke
core   +2 more sources

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke

Biomedicines, 2021
Cerebral ischemia is the second leading cause of death in the world and multimodal stroke therapy is needed. The ischemic stroke generally reduces the gene expression due to suppression of acetylation of histones H3 and H4.
Svetlana Demyanenko, Valentina Dzreyan, Svetlana Sharifulina   +2 more
doaj   +1 more source

Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]

, 2013
Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.
Eva Juengel, Jasmina Makarević, Axel Haferkamp, Georg Bartsch, Roman A Blaheta, Jüngel, Eva, Nelson, Karen, Blaheta, Roman A., Igor Tsaur, Makarević, Jasmina, Karen Nelson, Tsaur, Igor, Haferkamp, Axel, Bartsch, Georg, Juengel Eva, Makarević Jasmina, Blaheta Roman A., Nelson Karen, Tsaur Igor, Haferkamp Axel, Bartsch Georg   +20 more
core   +2 more sources

Dissecting the roles of histone deacetylase 1 and 2 in the hematopoietic system [PDF]

, 2008
Reversible histone acetylation on lysine residues has been intensively studied as an epigenetic mark for gene activation in a variety of eukaryotes. Histone deacetylases (HDACs) act to repress gene expression by removing acetyl groups from histones and ...
Yamaguchi, Teppei
core   +1 more source

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

Journal of Hematology & Oncology, 2009
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders.
Ma Yuehua, Cang Shundong, Liu Delong
doaj   +1 more source

Histone deacetylase inhibitors and transplantation [PDF]

Current Opinion in Immunology, 2007
Simply detecting the presence or absence of Foxp3, a transcription factor characteristic of naturally occurring CD4+ CD25+ regulatory T cells (Tregs), now appears of minimal value in predicting the outcome of immunologic responses, since dividing human CD4+ effector T cells can induce Foxp3 without attaining repressive functions, and additional ...
Ran, Tao, Edwin F, de Zoeten, Engin, Ozkaynak, Liqing, Wang, Bin, Li, Mark I, Greene, Andrew D, Wells, Wayne W, Hancock   +7 more
openaire   +2 more sources

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives

Experimental Hematology & Oncology
Histone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category have received approval from the U.S.
Jingjing Pu, Ting Liu, Xuzhen Wang, Amit Sharma, Ingo G. H. Schmidt-Wolf, Liping Jiang, Jian Hou   +6 more
doaj   +1 more source